

Edgar Filing: ICN PHARMACEUTICALS INC - Form DEFA14A

ICN PHARMACEUTICALS INC
Form DEFA14A
May 15, 2001

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant To Section 14(a) Of
The Securities Exchange Act Of 1934

Filed by the Registrant [X]

Filed by a Party other than the Registrant []

Check the appropriate box:

[] Preliminary Proxy Statement

[] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))

[] Definitive Proxy Statement

[X] Definitive Additional Materials

[] Soliciting Material Pursuant to Section 240.14a-12

ICN Pharmaceuticals, Inc.

(Name of Registrant as Specified in its Charter)

N/A

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X] No fee required.

[] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

[] Fee paid previously with preliminary materials.

[] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

Following is the text of a mailing sent to shareholders of ICN Pharmaceuticals,
Inc. on or about May 15, 2001:

ALERT!

ICN Annual Shareholder Meeting

Edgar Filing: ICN PHARMACEUTICALS INC - Form DEFA14A

Return your "White" Proxy Card

Call 1-800-223-2064 for a proxy card or more information

Your Shareholder Value Depends on Your Vote

ICN stockholders are strongly advised to read the proxy statement relating to ICN's 2001 annual meeting of stockholders, as it contains important information. Stockholders can obtain this proxy statement, any amendments to the proxy statement and other documents filed by ICN with the Securities and Exchange Commission without charge at the Internet website maintained by the Securities and Exchange Commission at www.sec.gov. In addition, ICN has mailed the proxy statement to each stockholder of record on the record date established for the stockholders meeting. ICN will also make additional copies of the proxy statement and any amendments to the proxy statement available without charge to ICN's stockholders. Please direct your request for the proxy statement to Investor Relations, ICN Pharmaceuticals, Inc., 3300 Hyland Avenue, Costa Mesa, California 92626, telephone (714) 545-0100, extension 3104 or to Georgeson Shareholder at (800)-223-2064.

If you have any questions or need assistance voting your shares, please call:

[LOGO - Georgeson GS Shareholder]

17 State Street, 10th Floor / New York, NY 10004
Call Toll-Free (800) 223-2064

It's Quick & Easy to Vote your "White" Proxy Card

How to Vote for ICN's Three Directors and Protect Shareholder Value

1. Check the box marked "For all nominees listed"
2. Sign your name and date it [GRAPHIC OMITTED - PHOTOGRAPH OF WHITE PROXY CARD]
3. Put your "white" proxy card in the return envelope provided and drop it in the mail box by Wednesday, May 23rd -- your postage has already been paid
4. Remember to return your "white" proxy

card by Wednesday, May 23rd. After

that date, call Georgeson Shareholder

regarding voting at 1-800-223-2064

NEED A PROXY CARD? HAVE A QUESTION? Call 1-800-223-2064

Vote for ICN's Three Directors

ICN Leadership is Putting Shareholders First